CA2465471C - Use of alkanoyl l-carnitine for the treatment of erectile dysfunction - Google Patents

Use of alkanoyl l-carnitine for the treatment of erectile dysfunction Download PDF

Info

Publication number
CA2465471C
CA2465471C CA2465471A CA2465471A CA2465471C CA 2465471 C CA2465471 C CA 2465471C CA 2465471 A CA2465471 A CA 2465471A CA 2465471 A CA2465471 A CA 2465471A CA 2465471 C CA2465471 C CA 2465471C
Authority
CA
Canada
Prior art keywords
erectile dysfunction
treatment
acid
carnitine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2465471A
Other languages
English (en)
French (fr)
Other versions
CA2465471A1 (en
Inventor
Aleardo Koverech
Andrea Lenzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2465471A1 publication Critical patent/CA2465471A1/en
Application granted granted Critical
Publication of CA2465471C publication Critical patent/CA2465471C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2465471A 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction Expired - Fee Related CA2465471C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001RM000708A ITRM20010708A1 (it) 2001-12-04 2001-12-04 Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
ITRM2001A000708 2001-12-04
PCT/IT2002/000758 WO2003047563A1 (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Publications (2)

Publication Number Publication Date
CA2465471A1 CA2465471A1 (en) 2003-06-12
CA2465471C true CA2465471C (en) 2010-10-19

Family

ID=11455907

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2465471A Expired - Fee Related CA2465471C (en) 2001-12-04 2002-12-04 Use of alkanoyl l-carnitine for the treatment of erectile dysfunction

Country Status (16)

Country Link
US (3) US20050080018A1 (https=)
EP (1) EP1450782B9 (https=)
JP (1) JP4370169B2 (https=)
KR (1) KR100907938B1 (https=)
AT (1) ATE309800T1 (https=)
AU (1) AU2002365847A1 (https=)
CA (1) CA2465471C (https=)
DE (1) DE60207442T2 (https=)
DK (1) DK1450782T3 (https=)
ES (1) ES2250749T3 (https=)
HU (1) HU229214B1 (https=)
IT (1) ITRM20010708A1 (https=)
MX (1) MXPA04005269A (https=)
PL (1) PL211211B1 (https=)
SI (1) SI1450782T1 (https=)
WO (1) WO2003047563A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040561A1 (it) * 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
AP2011005795A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
IT1397867B1 (it) * 2010-02-03 2013-02-04 Brotzu Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
FI4000608T3 (fi) 2013-04-18 2026-01-21 Boehringer Ingelheim Int Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä
JP6561136B2 (ja) * 2015-04-30 2019-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
KR20250097990A (ko) 2016-11-10 2025-06-30 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
DK0793962T3 (da) * 1996-03-04 2000-05-22 Sigma Tau Ind Farmaceuti Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
IT1293539B1 (it) * 1997-07-16 1999-03-01 Sigma Tau Ind Farmaceuti Composizione nutritiva per soggetti in stato di debilitazione causato da stress
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6241471B1 (en) * 1999-08-26 2001-06-05 General Electric Co. Turbine bucket tip shroud reinforcement
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di

Also Published As

Publication number Publication date
EP1450782A1 (en) 2004-09-01
DK1450782T3 (da) 2006-02-20
ITRM20010708A0 (it) 2001-12-04
CA2465471A1 (en) 2003-06-12
HU229214B1 (hu) 2013-09-30
HUP0402062A3 (en) 2012-09-28
ES2250749T3 (es) 2006-04-16
EP1450782B9 (en) 2006-05-17
AU2002365847A1 (en) 2003-06-17
KR20050044594A (ko) 2005-05-12
MXPA04005269A (es) 2004-10-11
PL371131A1 (en) 2005-06-13
US20070117762A1 (en) 2007-05-24
SI1450782T1 (sl) 2006-02-28
JP2005511655A (ja) 2005-04-28
JP4370169B2 (ja) 2009-11-25
ATE309800T1 (de) 2005-12-15
PL211211B1 (pl) 2012-04-30
EP1450782B1 (en) 2005-11-16
WO2003047563A1 (en) 2003-06-12
DE60207442T2 (de) 2006-07-27
ITRM20010708A1 (it) 2003-06-04
DE60207442D1 (de) 2005-12-22
US8343979B2 (en) 2013-01-01
US20050080018A1 (en) 2005-04-14
HUP0402062A2 (hu) 2005-02-28
KR100907938B1 (ko) 2009-07-16
US20120041005A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
US8343979B2 (en) Use of alkanoyl L-carnitine for the treatment of erectile dysfunction
US6372790B1 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
US20220151975A1 (en) Low-Dose Doxepin For Treatment Of Sleep Disorders In Elderly Patients
JP2002505681A (ja) 健常人における気分障害を調節するための組成物
US9238033B2 (en) Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine
NZ225053A (en) Use of doxazosin in pharmaceutical compositions for suppressing fibrosis and lipid deposition
TW589184B (en) Pharmaceutical composition for preventing or reversing diabetic cardiomyopathy
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
EP1569635B1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
CN101467992A (zh) L-肉碱用于治疗心血管疾病的用途
CN100408038C (zh) 用来治疗原发性头痛的复合维生素的应用
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
US7485642B2 (en) Method for treating septic shock
US8394854B2 (en) Use of L-carnitine for the treatment of cardiovascular diseases
Nies et al. Recent concepts in the clinical pharmacology of anithypertensive drugs
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191204